8.36
-0.1(-1.18%)
Currency In USD
Address
21 Firstfield Road
Gaithersburg, MD 20878
United States of America
Phone
240 268 2000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
952
First IPO Date
December 05, 1995
| Name | Title | Pay | Year Born |
| Mr. John Charles Jacobs M.B.A. | President, Chief Executive Officer & Director | 1.55M | 1967 |
| Mr. John Joseph Trizzino B.S., M.B.A. | President & Chief Operating Officer | 857,257 | 1960 |
| Mr. James Patrick Kelly C.F.A. | Executive Vice President, Chief Financial Officer & Treasurer | 880,849 | 1966 |
| Ms. Elaine O'Hara | Executive Vice President & Chief Strategy Officer | 991,316 | 1968 |
| Mr. Richard P. Crowley | Executive Vice President & Chief Operating Officer | 0 | 1957 |
| Mr. Troy Morgan Esq., J.D. | Senior Vice President, Deputy General Counsel & Chief Compliance Officer | 0 | 1971 |
| Ms. Silvia Taylor M.B.A. | Executive Vice President and Chief Corporate Affairs & Advocacy Officer | 0 | N/A |
| Dr. Henrietta Ukwu FACP FRAPS, M.D. | Executive Vice President & Chief Regulatory Officer | 0 | 1967 |
| Ms. Erika S. Trahan | Associate Director of Investor & Public Relations | 0 | N/A |
| Mr. Ian J. Watkins | Executive Vice President & Chief Human Resources Officer | 0 | 1963 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.